DoctorBonnie Bereznicki

Associate Head Learning and Teaching/Senior Lecturer

Medicine

  • Associate Head Learning and Teaching/Senior Lecturer
    Medicine
  • +61 3 6226 4624 (Work)
  • Tasmanian School of Medicine, Medicine, Level 2, 243-09 MS2, Hobart CBD Campuses, TAS

FUNDED PROJECTS

  • GRANT
    Adverse drug reaction-related hospital admission in elderly Australians with dementia
    1 Jan 2020 - 30 Jun 2021
    People funded by this grant:
    • Parameswaran Nair N,
    • Bereznicki L,
    • Adamczewski B,
    • Salahudeen M,
    • Bereznicki B
    Project Total: $9,985; Dementia is a significant risk factor for serious side effects of medicines or adverse drug reactions (ADRs). This prospective study will investigate and identify the prevalence and risk factors for ADR-related hospital admissions in elderly patients with dementia or cognitive impairment. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,985); University of Tasmania.
  • GRANT
    What is the economic impact of allergic respiratory disease in Tasmania?
    1 May 2019 - 31 Dec 2019
    People funded by this grant:
    • Johnston F,
    • Palmer A,
    • Jones P,
    • Bereznicki B,
    • Cooling N
    Project Total: $10,000; This project will provide the first economic assessment of the burden of allergic respiratory disease (allergic rhinitis and allergic asthma) in Tasmania. Together, allergic rhinitis and allergic asthma affect over 20% of the Tasmanian population, yet there has been no rigorous analysis of the health and economic impacts. This project will cost the direct and indirect costs of these conditions across Tasmania. In doing so, we will provide a rigorous evidence base to build a case for allergic respiratory research, and directly inform government and non-government investment in interventions. Our research will be co-designed with expert input from government and non-government stakeholders (Asthma Australia) to ensure alignment with end-user needs. Funded by: University of Tasmania - Grant-Research Enhancement Program; University of Tasmania ($10,000).
  • GRANT
    Preventing Adverse Drug Reactions in the Elderly
    1 Jan 2019 - 30 Jun 2023
    People funded by this grant:
    • Bereznicki L,
    • Curtain C,
    • Bereznicki B,
    • Cousins J,
    • Connolly M
    Project Total: $274,000; Based on our prospective adverse drug reaction (ADR) registry:1 * 15% of medical admissions to Tasmanian public hospitals in elderly patients were ADR-related, * 89% were preventable, * 17% patients had a repeat ADR within 12 months, and * One third of patients with repeat ADRs experienced the same ADR caused by the same medications. From this clinical registry, we developed and validated an ADR risk prediction score (PADR-EC).2 We hypothesise that ADR risk stratification during hospitalisation and communication of this risk, together with recommendations that target the specific risk factors identified, to GPs at discharge will reduce the risk of ADR-related hospitalisation. Design: A randomised controlled trial (RCT) at the Royal Hobart Hospital, the major public hospital in Tasmania. Population: Over 12-months, 1000 patients ≥65 years with unplanned admissions to medical wards will be recruited and randomly allocated to intervention or control groups. Intervention: A researcher will perform an ADR risk assessment using the PADR-EC Score,2 which is the sum of points assigned to 5 independent predictors of ADR-related hospitalisation. Based on the PADR-EC Score and the specific risk factors identified, recommendations to reduce the risk of ADRs will be determined. Recommendations will relate to: * post-discharge medication management services, * monitoring of specific parameters/medications, and * de-prescribing strategies. The PADR-EC Score and recommendations will be communicated to the patient and clinical team during hospitalisation, and the patient's GP, alongside the usual information, in the electronic discharge summary. Control: Usual hospital care, with GPs receiving the standard discharge summary. Follow up: All participants will be followed by the research team for 12-months to identify ADRs (including their management and outcome) and health services received. Outcomes: ADR-related hospitalisation (primary); ADRs requiring hospital treatment, change in therapy or specific treatment (secondary). The study will be powered to detect a 5% difference in the primary outcome Funded by: Hospitals Contribution Fund Research Foundation - HCF - Grant-Health Services Research Program ($274,000); University of Tasmania.
  • GRANT
    Getting Asthma Under Control
    3 Nov 2017 - 30 Jun 2020
    People funded by this grant:
    • Armour C,
    • Krass I,
    • Bosnic-Anticevich S,
    • Saini B,
    • Bereznicki L
    Project Total: $2,074,100; We will conduct a cluster randomised trial, with asthma control being the main inclusion criterion and clinical outcome measured. The three study arms are: Group A (Pharmacy Asthma Service): eligible patients will receive four private consultations with the pharmacist, at baseline, one month, six months (via telephone) and 12 months. The consultations will focus on addressing three key factors associated with uncontrolled asthma: suboptimal adherence characterised by underuse of preventer medication and/or overuse of reliever medication; suboptimal inhaler technique; and/or uncontrolled allergic rhinitis. At each visit, asthma control and a number of secondary outcomes will be assessed. Group B (Low intervention and referral): Patients identified with uncontrolled asthma by the pharmacist will be referred to their general practitioner. Clinical outcomes will be assessed at one month and 12 months. Group C (Usual Care): The third group will be recruited from a comparable sample of patients with asthma, matched by age, gender and asthma control scores from general practice medical records. Asthma control and secondary outcomes for this group will be assessed by the project group at baseline and 12 months. Funded by: Department of Health, Disability and Ageing (Cth) - Pharmacy Trial Program (Tranche 2); Woolcock Institute of Medical Research; University of Tasmania.
  • GRANT
    Investigating the burden of childhood fever on Tasmanian families and the Royal Hobart Hospitals Emergency Department.
    1 Jan 2016 - 31 Dec 2016
    People funded by this grant:
    • Bereznicki B,
    • Beggs S,
    • Bereznicki L,
    • Zosky G
    Project Total: $9,599; This project will describe the presentations to the Royal Hobart Hospital emergency department by children with fever, investigate the knowledge, beliefs and perceptions about childhood fever among parents and caregivers in Tasmania, and develop an educational package for parents and caregivers about childhood fever. Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($9,599); University of Tasmania.
  • GRANT
    Understanding the discrepancy between perceived and actual asthma control in Australia
    1 Jan 2015 - 31 Dec 2015
    People funded by this grant:
    • Bereznicki B
    Project Total: $10,848; Funded by: University of Tasmania - Grant-Research Enhancement (REGS); University of Tasmania ($10,848).
  • CONSULTANCY/CONTRACT RESEARCH
    A Review of the Management of Childhood Asthma in Tasmania
    1 Jan 2011 - 31 Dec 2011
    People funded by this grant:
    • Bereznicki B,
    • Bereznicki L
    Project Total: $5,500; Funded by: Asthma Foundation of Tasmania ($5,500); University of Tasmania.
  • GRANT
    Building on Success: The Sustainability and National Feasibility of a Community Pharmacy Intervention to Improve the Management of Asthma
    14 Oct 2008 - 29 May 2009
    People funded by this grant:
    • Peterson G,
    • Bereznicki B,
    • Jackson S,
    • Walters H
    Project Total: $52,655; Funded by: Asthma Foundations of Australia - Grant-Targeted Intervention Grants ($52,655); University of Tasmania.
  • GRANT
    Pharmacy Dispensing Records to Identify and Educate Patients with Suboptimal Asthma Management
    29 Feb 2008 - 30 Nov 2009
    People funded by this grant:
    • Jackson S,
    • Peterson G,
    • Bereznicki B,
    • Gee P,
    • Fitzmaurice K
    Project Total: $192,986; Funded by: Department of Health and Aged Care - Grant-PGA Pharmacy Guild-Investigator Initiated ($192,986); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Understanding respiratory persistence in Australian patients with COPD
    1 Dec 2007 - 31 Dec 2008
    People funded by this grant:
    • Jackson S,
    • Bereznicki B,
    • Gee P,
    • Fitzmaurice K,
    • Peterson G
    Project Total: $105,880; Funded by: Boehringer Ingelheim Pty Ltd ($105,880); University of Tasmania.